Human herpesvirus 6 (HHV-6) was discovered as a novel human herpesvirus in the peripheral blood of patients with lymphoproliferative disorders and AIDS. While it was originally designated "human B-lymphotropic virus" (1), subsequent studies established that the virus was primarily T-cell lymphotropic, causing it to be classified as 
Human herpesvirus 6 (HHV-6) was discovered as a novel human herpesvirus in the peripheral blood of patients with lymphoproliferative disorders and AIDS. While it was originally designated "human B-lymphotropic virus" (1), subsequent studies established that the virus was primarily T-cell lymphotropic, causing it to be classified as HHV-6. In most children, primary HHV-6B infection causes exanthem subitum (2), a common febrile illness in infants, occurs between 6 months and 1 year of age (3)
.
HHV-6 probably remains latent in the body after the primary infection, then reactivates upon host immunosuppression in a manner similar to other human herpesviruses. All previously-identified human herpesviruses, especially human cytomegalovirus (HCMV), are important contributors to morbidity and mortality in immunosuppressed organ transplant recipients. As HHV-6 shares many characteristics with HCMV, including DNA sequence homology, elements of genomic organization, antigenic cross-reactivity, and in-vitro growth characteristics, HHV-6 may behave similarly as a complication of organ transplantation. Although the pathogenesis of HHV-6 is not well understood, recent evidence suggests that the virus is a serious, potentially lifethreatening pathogen in the post-transplant period (10). Although the exact frequency of reactivation is difficult to determine, approximately 40% to 50% of transplant recipients develop HHV-6 infection around 2 to 4 weeks after transplantation. The incidence appears to be dependent on the sensitivity of the procedures for the diagnosis of viral infection. Although numerous clinical syndromes have been postulated as HHV-6-associated diseases (
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